top of page

Celonic launches the new GS-CHOvolution® system based on Revvity’s CHOSOURCE™ expression platform

New system replaces Celonic’s current CHOvolution® CHO-K1 cell line development offering for monoclonal antibodies (mAbs) and complex proteins.

Celonic and Revvity have signed a commercial license agreement for Revvity’s CHOSOURCE™ expression platform including TnT transposon technology, which will be used in combination with Celonic’s expertise and workflows for cell line development.  

BASEL, SWITZERLAND, March 18, 2024. Celonic’s GS-CHOvolution® will offer Revvity’s gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO-K1) cGMP-compliant cell line, including TnT transposon technology, which accelerate and streamline the selection of high expressing clones during cell line development.

The benefits of a CHO cell line with GS selection system when used in combination with a transposon-based expression vector include:

  • Well established industry standard for biomanufacturing;

  • Recognized by regulators as suitable for the manufacture of Biologics;

  • Accelerates cell line development timelines with high efficiency cell line screening;

  • Suitable for monoclonal antibodies (mAbs) and complex proteins.

Celonic’s GS-CHOvolution® will offer small to large Biotech Customers a simplified License fee model without royalties, and a platform that will be competitive with that proposed by larger Contract Development and Manufacturing Organizations (CDMO) and Big Pharma Customers.

Dr. Samanta Cimitan, CEO Celonic Group, commented: “We are delighted to partner with Revvity to provide our customers a state of the art GS expression platform with a track record of success which complements Celonic’s early phase offering. We are committed to bringing our customers of all sizes, expertise, agility and solutions to develop and manufacture life improving drugs effectively and efficiently.”

Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated: “Celonic and Revvity are likeminded organizations, we both seek to enable our customers and help advance the biotherapeutics of tomorrow. We are very pleased that Celonic has chosen the CHOSOURCE expression platform for their contract development and manufacturing services. Our well-established cGMP manufacturing CHO cell line has over 65 INDs filed globally and empowers companies to accelerate and streamline biotherapeutic development programs from DNA to clinical manufacturing. But what truly differentiates Revvity is our commitment to the evolution of our platforms and ongoing collaboration with our partners to achieve their current, as well as future, development and manufacturing needs.”


bottom of page